PROPOFOL
Urologic Neoplasms
Hitit UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Urologic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Astellas Pharma Global Development, Inc. | Phase 2 | BB |
su011248 AstraZeneca | Phase 3 | B |
VOLITINIB AstraZeneca | Phase 3 | B |
MOTEXAFIN GADOLINIUM HYDRATE | Phase 2 | B |
NKT2152 NiKang Therapeutics, Inc. | Phase 2 | CCC |
View all 24 →
Same molecule, other indications
PROPOFOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →